Dermatophytic Onychomycosis Therapeutics Market

Dermatophytic Onychomycosis Treatment Market – Overview

Dermatophytic Onychomycosis is a disease caused by fungus occurring in the fingernails or toenails. Also known as tinea unguium, this fungal disease may also cause ring infection over the nails. The fungi responsible for Dermatophytic Onychomycosis are trichophyton rubrum, and trichophyton mentagrophytes. One of the key factor augmenting the growth of this market is the increasing prevalence of this disease especially among the geriatric population as with age, people tend to miss out on minor cleaning areas, thereby leading to an irregular hygiene maintenance of their fingernails and toenails.

Nail fungi is common to occur among people who are ignorant of their hygiene habits and among people who are prone to various diseases such as diabetes. Fungal infection is also a common phenomenon that is more common amongst the elderly population. The rising cases of chronic diseases stand as a key factor augmenting the growth of this market.

The report on the global Dermatophytic Onychomycosis Treatment market is based on a thorough analysis of the market and offers both qualitative and quantitative approach. The key driving, repelling, and challenging factors of the market are discussed in details with the possibility of new growth opportunities. Besides this, the report also studies the impact of the novel COVID19 pandemic and mentions the key strategies adopted by players to ensure significant revenue generation during the forecast period. It also throws light on the key segments and the names of the leading segment and factors attributing to its growth.

Dermatophytic Onychomycosis Treatment Market – Competitive Landscape

The nature of market for Dermatophytic onychomycosis treatment is highly competitive on account of the presence of multiple players. Some of them are indulging themselves in joint ventures and merger and acquisition strategies to ensure a notable position for their brand in the overall market competition. On the other side, some other players are focusing on brand expansion and are therefore making huge investments on research and development activities to gain a competitive edge in the overall market competition.

Some of the key players of the global Dermatophytic Onychomycosis Treatment market include:

• Medimetriks Pharmaceuticals Inc.
• Dr.Reddy’s Laboratories Ltd.
• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Galderma S.A.
• Cipla Ltd.
• Bayer AG
• Moberg Pharma AB
• Novartis AG
• Valeant Pharmaceuticals Inc.
• Other players

Dermatophytic Onychomycosis Treatment Market – Innovation

• The Food and Drug Administration approved a supplemental drug application for JUBLIA topical solution in April 2020. This efinazonazole topical solution was launched in June 2014 and was previously approved for 18 year old or older. With the 2020 approval, this new drug application can be used on children above the age of 6 years as well.

Dermatophytic Onychomycosis Treatment Market – Growth Drivers

People diagnosed with chronic diseases such as peripheral vascular diseases, psoriasis, and diabetes mellitus are prone to contract Dermatophytic Onychomycosis. This acts as a key driver promoting the growth of this market. Besides this, people with HIV-positive, genetic predisposition, and athlete’s foot also contract this disease, the prevalence of which will further augment the growth of this market. On the contrary, the rising inclination towards maintaining personal hygiene especially triggered during the coronavirus pandemic may pose a challenge for this market. Nevertheless, the presence of a high diabetic and heart disease patient pool across the world and their vulnerability towards various diseases will help the market generate notable revenue in the coming years as well.

Dermatophytic Onychomycosis Treatment Market – Geographical Insights

Geographically, North America held the largest share and is likely to continue so during the forecast period as well. Factors such as presence of high geriatric population and their vulnerability to various chronic diseases are responsible for the growth of the North American market. Besides this, the presence of a well-established medical infrastructure and facilities in the developed nations will also help attract significant revenues for this regional market in the forecast period. Furthermore, the growing awareness about this kind of fungal disease and the availability of treatment options will further create new growth opportunities for this regional market in the years that follow.